FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

On July 31, 2009, the U.S. Food and Drug Administration granted approval for the use of bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA) in combination with interferon (IFN)-α2a for the treatment of patients with metastatic renal cell carcinoma. The approval was primarily based on re...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Summers, Jeff, Cohen, Martin H., Keegan, Patricia, Pazdur, Richard
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2010
Teme:
Regulatory Issues: FDA
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227879/
https://ncbi.nlm.nih.gov/pubmed/20061402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0250
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki